Biočipové technologie se začaly rozvíjet zhruba před 10 lety a jejich použití stálé vzrůstá a rozšiřuje se množství jejich aplikací. Od základní aplikace na problematiku molekulárně genetickou, kdy analyzovanou substancí byly nukleové kyseliny, se postupně jejich používání rozšířilo i na bílkoviny, cukry a alespoň co se týká používaného označení i na buňky a tkáně. Vývoj se ubíral v zásadě dvěma směry, směrem k neustálému zvětšování počtu současně prováděných detekcí a směrem k čipům specializovaným na řešení určitých specifických otázek.

Biochip technologies have arisen and expanded during the last decade and the scope of them is now very broad. At the very beginning the analyzed substance was nucleic acid, but also proteins and carbohydrates (sugars) became the targets and the same term covers also cells and tissues now. The technology evolved by increasing the number of detections made simultaneously on one chip and reached the possibility to test all human genes at once, the other way led to specific sets with limited number of probes e.g. all known mutations of one gene, or genes participating in one pathway or function.

• MeSH
• Protein Array Analysis methods   trends   utilization   MeSH
• Molecular Diagnostic Techniques methods   instrumentation   utilization   MeSH
• Financing, Organized MeSH
• Genomics methods   trends   MeSH
• Medical Oncology methods   trends   MeSH
• Humans MeSH
• Microchip Analytical Procedures methods   utilization   MeSH
• Nanotechnology methods   trends   MeSH
• Oligonucleotide Array Sequence Analysis methods   trends   utilization   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Review MeSH

AIM: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with acute lymphoblastic leukemia (ALL) and in healthy subjects using biochip array technology. This approach allows multi-analytical determination from a single sample. METHODS: A total of 15 ALL patients and 15 healthy subjects (blood donors) were studied. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. T-tests were used for statistical analysis. RESULTS: Comparing cytokine and adhesion molecule levels in ALL patients and in healthy subject, we found significant increase in serum VCAM-1 (p < 0.000001), ICAM-1 (p < 0.0001), L-selectin (p < 0.0001), IL-8 (p < 0.001), MCP-1 (p < 0.01), and significant decrease (p < 0.01) in serum IL-3 and IL-4. CONCLUSION: Our results indicate that serum levels of specific cytokines and adhesion molecules (VCAM-1, ICAM-1, L-selectin, IL-8, IL-3, IL-4, MCP-1) are significantly altered in patients with newly diagnosed ALL, reflecting acti-vity of the disease. Further investigation is needed to establish if these alterations could be used as a prognostic indicator for ALL.

• MeSH
• Precursor Cell Lymphoblastic Leukemia-Lymphoma blood   MeSH
• Protein Array Analysis methods   MeSH
• Cytokines blood   MeSH
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Cell Adhesion Molecules blood   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

AIMS: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients treated for acute myeloid leukemia (AML) using biochip array technology. This approach allows multi-analytical determination from a single sample. METHODS: A total of 15 AML patients were studied. Blood samples were taken at the diagnosis (active leukemia) and at circa 6 months after completion of last chemotherapy (durable complete remission in all patients). RESULTS: Comparing cytokine and adhesion molecule levels in active leukemia and in durable complete remission, we found significant increase (P<0.01) in serum interleukin-7 (IL-7), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and significant decrease (P<0.01) in serum E-selectin. DISCUSSION: Our results indicate that serum levels of specific cytokines and adhesion molecules (IL-7, EGF, VEGF, E-selectin) are significantly altered in patients treated for AML, reflecting activity of the disease. Further investigation is needed to establish if the changes observed in the levels of these molecules could be used as a prognostic indicator of AML.

• MeSH
• Leukemia, Myeloid, Acute blood   drug therapy   MeSH
• Protein Array Analysis MeSH
• Cytokines blood   MeSH
• Middle Aged MeSH
• Humans MeSH
• Cell Adhesion Molecules blood   MeSH
• Pilot Projects MeSH
• Vascular Endothelial Growth Factor A MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

Cíl sdělení: Byly sledovány analytické a klinické vlastnosti technologie proteinových biočipů pro imunochemická stanovení kardiálních markerů a jejich možné využití v diagnostice infarktu myokardu. Metodika: Stanovení hladiny kardiálních markerů (CKMB, MYO, GPBB, H-FABP, CAIII a cTnI) bylo provedeno systémem Evidence Investigator (Randox). Pro jednotlivé kardiální markery stanovené panelem Cardiac Array byly hodnoceny analytické parametry testu. Kardiální markery byly stanoveny ve vzorcích sér 28 pacientů (21 mužů, 7 žen, věk 47–86 let) s diagnózou akutního infarktu myokardu. Výsledky a závěry: Mezilehlá přesnost pro všechny analyty, kromě myoglobinu, je ve shodě s výrobcem (CV < 10%). H-FABP i GPBB jsou časnými markery akutního infarktu myokardu, přičemž H-FABP má pravděpodobně vyšší diagnostickou senzitivitu než myoglobin. Dá se očekávat, že stanovení kardiálních markerů proteinovými biočipy do budoucna najde své uplatnění v biochemické diagnostice poškození myokardu.

Objective: The analytical and clinical performance of protein biochip technology of immunochemical analysis of cardiac markers and their use in diagnosis of acute myocardial infarction were evaluated. Method: Determination of concentration of cardiac markers (CKMB, MYO, GPBB, H-FABP, CAIII and cTnI) was performed by system Evidence Investigator (Randox). Analytical parameters of Cardiac array were tested. Markers of myocardial injury were determined in group of the 28 patients (21 men, 7 women, age 47–86 years) with acute myocardial infarction diagnosis. Results and conclusions: Reproducibility of all tests agree with data of producer (CV < 10%), except myoglobin assay. New substances H-FABP and GPBB are promising early markers of acute myocardial infarction and diagnostic sensitivity of H-FABP would be better than myoglobin test. In future, determination of new cardiac markers by protein biochips technology probably will be used in cardiologic diagnosis.

• MeSH
• Biomarkers blood   MeSH
• Protein Array Analysis instrumentation   utilization   MeSH
• Financing, Organized MeSH
• Glycogen Phosphorylase blood   MeSH
• Myocardial Infarction blood   MeSH
• Carbonic Anhydrase III blood   MeSH
• Humans MeSH
• Necrosis blood   MeSH
• Fatty Acid-Binding Proteins blood   MeSH
• Serum MeSH
• Troponin blood   MeSH
• Check Tag
• Humans MeSH

Východisko. Multianalytový přístup je doporučován pro rychlou diagnostiku a stratifikaci rizika akutního koronárního syndromu. Testovali jsme analytickou vhodnost technologie proteinových biočipů pro stanovení kardiálních markerů. Metody. Analýza kardiálních markerů: CK-MB mass, cTnI, myoglobinu, glykogen fosforylázy BB (GPBB), srdečního typu proteinu vázajícího mastné kyseliny (h-FABP) a karboanhydrázy III (CAIII) bylo provedeno systémem Evidence Investigator (Randox). Byly testovány analytické parametry soupravy Cardiac array. Výsledky získané systémem Evidence Investigator byly porovnány s hodnotami měřenými metodami na stanovení CK-MB mass a myoglobinu pro Elecsys 2010 (Roche). Markery poškození myokardu byly měřeny u 28 dárců krve, 28 pacientů s akutním infarktem myokardu a 21 pacientů po chemoterapii antracykliny (monitorování kardiotoxicity). Výsledky. Passing-Bablokova regrese ukazuje statisticky významné rozdíly ve výsledcích. Důvodem těchto odchylek je nedostatečná standardizace metod a diskrepance mezi kalibracemi. Nové analyty h-FABP a GPBB jsou slibnými časnými markery akutního infarktu myokardu a diagnostická sensitivita h-FABP by mohla být vyšší než u myoglobinu. Tyto markery mohou být užitečné pro monitoring kardiotoxicity antracyklinů. Závěry. Použití biočipové technologie v kardiologické diagnostice představuje výzvu do budoucna, ale bude nutná dokonalejší standardizace imunochemických metod.

Background. Multi-marker approach is recommended for rapid diagnostics and risk stratification of acute coronary syndrome. We tested the analytical performance of protein biochip technology for determination cardiac markers. Methods. Analysis of cardiac markers: CK-MB mass, cTnI, myoglobin, glycogen phosphorylase BB (GPBB), heart type of fatty acid binding protein (h-FABP) and carbonic anhydrase III (CAIII) was performed by system Evidence Investigator (Randox). Analytical parameters of Cardiac array were tested. The Evidence Investigator results were compared with Elecsys 2010 (Roche) CK-MB mass and myoglobin methods. Markers of myocardial injury were determined in 28 blood donors, 28 patients with acute myocardial infarction diagnosis and 21 patients after chemotherapy containing anthracyclines (monitoring of cardiotoxicity). Results. The Passing-Bablok regression shows statistically significant differences in results. The reasons for these differences are poor standardization of methods and discrepancies between calibrations. New substances h-FABP and GPBB are promising early markers of acute myocardial infarction and diagnostic sensitivity of h-FABP would be better than myoglobin test. These markers can be useful for monitoring of cardiotoxicity of anthracyclines. Conclusions. In future, the use of biochip technology in cardiology diagnostic represents an important challenge but it is a necessary standardization of immunochemical methods.

• MeSH
• Acute Coronary Syndrome diagnosis   MeSH
• Biomarkers blood   MeSH
• Protein Array Analysis MeSH
• Middle Aged MeSH
• Humans MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH

Cílem studie je sledování CK MB izoenzymu kreatinkinázy (CK MB mass), myoglobinu (MYO), BB izoenzymu glykogenfosforylázy (GPBB), srdečního typu proteinu vázajícího mastné kyseliny (H-FABP), karboanhydrázy III (CAIII) a srdečního troponinu I (cTnI) u pacientů s akutním infarktem myokardu v průběhu 5 dnů a prověření citlivosti nové technologie proteinových biočipů použitých k jejich stanovení (systém Evidence Investigator™ firmy Randox (Randox Laboratories Ltd., Velká Británie). H-FABP byl výrazně zvýšen u většiny pacientů již při prvním odběru (maximální hladina H-FABP 78,9 µg/l, ± 62,9 µg/l, vs. normální hodnota 1,8 µg/l, ± 0,6 µg/l, P < 0,00001) a měl nejvyšší senzitivitu při vyhledávání přítomnosti nekrózy. CKMB mass a cTnI dosáhly vrcholu při druhém odběru (maximální hodnota CKMB mass 30,6 µg/l, ± 25,59 µg/l oproti normální hodnotě, P < 0,00001 a cTnI 20,0 µg/l, ± 17,6 µg/l vs. normální hodnota, P < 0,00001). Hladina GPBB byla zvýšena v časné fázi AIM s pozvolným poklesem při druhém a třetím odběru, stejně jako hodnota CAIII. Jsou zde měřeny a srovnávány nové parametry jako GPBB, H-FABP nebo CA III, které mají vztah k akutnímu infarktu myokardu nebo zvyšují specificitu standardně stanovovaných kardiomarkerů při akutním infarktu myokardu (poměr MYO/CA III se osvědčil k diagnostice reinfarktu).

The aim of the study was the monitoring of plasma levels of isoenzyme of creatine kinase (CKMB mass), myoglobin (MYO), BB isoenzyme of glycogen phosphorylase (GPBB), heart-type fatty acid binding protein (H-FABP), carbonic anhydrase III (CA III), and cardiac troponin I (cTnI) in patients with acute myocardial infarction during 5 days as well as screening of the sensitivity of the new technology of the protein biochip microarray that was used to assess plasma levels of these markers (System Evidence Investigator™, Randox Laboratories Ltd., Great Britain). The plasma level of H-FABP was markedly elevated in major part of patients in the first measurement (the peak of plasma H-FABP 78,9 µg/l, ± 62,9 µg/l, vs. normal value 1,8 µg/l, ± 0,6 µg/l, P < 0,0001) and has the highest sensitivity for the determination of the necrosis. The peak of plasma CKMB mass and cTnI was elevated throughout the time of the second measurement (the peak of plasma CK MB mass 30,6 µg/l, ± 25,59 µg/l, vs. normal value, P < 0,0001 and cTnI 20,0 µg/l, ± 17,6 µg/l vs. normal value, P < 0,0001). The plasma GPBB level was increased during the first measurement and the GPBB level slow decreased to the normal value. The CAIII plasma level had the same course as the GPBB plasma level. In conclusion, we established new parameters (GPBB, H-FABP or CA III) that have relation to the acute myocardial infarction and increase the specificity of standard markers of through the acute myocardial infarction (and for MYO/CA III in the diagnosis of the re-infarction).

• Keywords
• kardiomarkery,
• MeSH
• Biomarkers blood   MeSH
• Protein Array Analysis methods   instrumentation   utilization   MeSH
• Financing, Organized MeSH
• Myocardial Infarction blood   MeSH
• Humans MeSH
• Check Tag
• Humans MeSH

Cíl studie: Tato práce sleduje pacienty s akutním koronárním syndromem a k diagnostice akutního infarktu myokardu (AIM) využívá zcela nové technologie proteinových biočipů. Snahou je nejenom ohodnotit tuto novou možnost laboratorní diagnostiky AIM, ale také srovnání méně známých kardiomarkerů se standardními markery a posouzení jejich vztahu ke klinickým parametrům. Materiál a metody: Do studie bylo celkem zařazeno 44 pacientů s diagnózou AIM a krevní odběry byly prováděny v den přijetí, za 24 hodin a poté čtvrtý nebo pátý den hospitalizace. Z kardiomarkerů byl testován panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP a GPBB) na biočipovém analyzátoru The Evidence InvestigatorTM od firmy Randox (Randox Laboratories Ltd., Velká Británie). Výsledky: Naše práce potvrdila těsný vztah FABP a GPBB k AIM a na základě jejich dynamiky je můžeme považovat za časné kardiomarkery. Zároveň jsme zjistili, že FABP má, stejně jako standardní marker CKMB nebo TnI, také prognostický význam - vyšší hodnoty jsou spojené se systolickou dysfunkcí. Také jsme poukázali na možnost využití biočipového analyzátoru při diagnostice AIM, kdy za poměrně krátký časový úsek získáme výsledky několika analytů najednou, které nám tak podají širší informace o probíhajícím AIM. Závěr: Metoda proteinových biočipů představuje v diagnostice AIM nový efektivní přístup, který ale jistě ke svému rozšíření vyžaduje řadu dalších studií.

Objective: This study observes patients with acute coronary syndromes. To the diagnosis of acute myocardial infarction (AIM) we use the new proteins biochip technologies. The aim of this study is to evaluate the new strategy of laboratory diagnostic method and to confront the less known's cardio markers with the standard markers and with the clinical parameters. Material and methods: This study contains 44 patients with AIM and the blood samples were taken in the time of the admission, 24 hours later and then the fourth or fifth day of hospitalization. We tested the cardiac panel Cardiac Array (cTnI, CK MB, myoglobin, CAIII, FABP and GPBB) on the biochip analyser The Evidence InvestigatorTM from Randox (Randox Laboratories Ltd., United Kingdom). Results: Our study confirms the close relationship between FABP and GPBB to AIM and we can consider these markers as early markers in the diagnosis of AIM. FABP has, as the standard markers CKMB or TnI, the prognostic value too (the higher values are associated with the systolic dysfunction). This study employs a new strategy of the biochip analyser in the diagnosis of AIM (in the same time we have the concentrations of more parameters and complex information about AIM). Conclusion: This method presents new interesting multianalytes approach to the diagnosis of the AIM. But this method requires a lot of further studies to verify this technology.

• MeSH
• Acute Disease MeSH
• Biomarkers * analysis   blood   MeSH
• Protein Array Analysis * methods   instrumentation   utilization   MeSH
• DNA Probes MeSH
• Ventricular Dysfunction, Left diagnosis   MeSH
• Glycogen Phosphorylase analysis   MeSH
• Myocardial Infarction diagnosis   MeSH
• Myocardial Ischemia * diagnosis   MeSH
• Carbonic Anhydrases diagnostic use   MeSH
• Creatine Kinase diagnostic use   MeSH
• Middle Aged MeSH
• Humans MeSH
• Myoglobin analysis   MeSH
• Fatty Acid-Binding Proteins analysis   MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Troponin analysis   MeSH
• Check Tag
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged, 80 and over MeSH
• Aged MeSH
• Female MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH

AIM: Evaluation of serum levels of 17 cytokines and 5 adhesion molecules in patients with newly diagnosed acute myeloid leukemia (AML) and in healthy subjects using biochip array technology. METHODS: A total of 15 AML patients and 15 healthy subjects (blood donors) were studied. Serum samples were analyzed by biochip based immunoassays on the Evidence Investigator analyzer. This approach allows multi-analytical determination from a single sample. T-tests were used for statistical analysis. RESULTS: In newly diagnosed AML patients, we found significant increase (p < 0.01) in serum VCAM-1, ICAM-1, E-selectin, L-selectin, and significant increase (p < 0.05) in serum IL-6, IL-8. No significant differences were found in the levels of other evaluated cytokines and adhesion molecules. CONCLUSION: Our results indicate that serum levels of specific cytokines and adhesion molecules (VCAM-1, ICAM-1, E-selectin, L-selectin, IL-6, IL-8) are significantly altered in patients with newly diagnosed AML, showing activity of the disease. Whether these alterations could serve as a prognostic marker for AML is not known. Further studies will be needed to define the potential role of these and additional markers in the risk stratification of AML.

• MeSH
• Leukemia, Myeloid, Acute blood   genetics   pathology   MeSH
• Vascular Cell Adhesion Molecule-1 blood   MeSH
• Protein Array Analysis methods   MeSH
• Cytokines blood   MeSH
• Adult MeSH
• E-Selectin blood   MeSH
• Interleukin-6 blood   MeSH
• Interleukin-8 blood   MeSH
• L-Selectin blood   MeSH
• Middle Aged MeSH
• Humans MeSH
• Intercellular Adhesion Molecule-1 blood   MeSH
• Cell Adhesion Molecules blood   MeSH
• Biomarkers, Tumor blood   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Female MeSH
• Publication type
• Journal Article MeSH
• Research Support, Non-U.S. Gov't MeSH

BACKGROUND: Human colostrum and milk contain components that influence development. Our aim was to use a protein array to determine the cytokine profile of human lacteal secretions and changes that occur during the early postpartum period. METHODS: We collected 17 samples of colostrum during the first 2 days postpartum and a 2nd group of 5 sets of 2 to 3 sequential colostrum or milk samples (at 20- to 30-h intervals). We analyzed the samples with array membranes consisting of 42 or 79 antibodies directed against cytokines. RESULTS: In most samples, we detected the previously described cytokines interleukin-8 (IL-8)/CXCL8, epidermal growth factor (EGF), growth-related oncoprotein (GRO)/CXCL1-3, angiogenin, transforming growth factor beta-2, and monocyte chemotactic protein 1 (MCP-1/CCL2). In addition, we found 32 cytokines that have not been described before in colostrum. Cytokine concentrations differed among mothers, and the spectrum of cytokines changed with time after delivery. A significant decrease occurred in IL-12 and macrophage inflammatory protein-1delta/CCL15 and a significant increase in MCP-1/CCL2. The production of angiogenin, vascular endothelial growth factor, GRO/CXCL1-3, EGF, and IL-8/CXCL8 remained high throughout. The concentrations of 2 selected cytokines measured with the array technique and ELISA showed moderate to strong correlation (r = 0.63 for EGF and r = 0.84 for IL-8/CXCL8). CONCLUSION: Despite the lack of precise quantification, the protein array might be suitable for cytokine screening. It allows simultaneous detection of a broad spectrum of cytokines (including those not described before) in lacteal secretions.

• MeSH
• Time Factors MeSH
• Chemokines analysis   MeSH
• Protein Array Analysis MeSH
• Cytokines analysis   MeSH
• Adult MeSH
• Enzyme-Linked Immunosorbent Assay MeSH
• Financing, Organized MeSH
• Colostrum chemistry   MeSH
• Humans MeSH
• Milk, Human chemistry   MeSH
• Intercellular Signaling Peptides and Proteins analysis   MeSH
• Postpartum Period MeSH
• Proteomics MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Female MeSH
• Publication type
• Comparative Study MeSH

• Publication type
• Abstracts MeSH